Recent studies reported that SLC22A1 rs3798168, rs683369, and rs628031 could affect the response to imatinib therapy in chronic myeloid leukemia (CML) patients [37, 38]. This evidence concerns the gene SLC22A1 and chronic myelogenous leukemia, BCR-ABL1 positive.